Preparation and evaluation of an astatine-211-labeled sigma receptor ligand for alpha radionuclide therapy
Authors:
- 1 November 2015
- journal article
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (11) , 875-879
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding siteNature Communications, 2011
- Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disordersExpert Opinion on Therapeutic Targets, 2011
- Sigma Receptors in Oncology: Therapeutic and Diagnostic Applications of Sigma LigandsCurrent Pharmaceutical Design, 2010
- Evaluation of radioiodinated vesamicol analogs for sigma receptor imaging in tumor and radionuclide receptor therapyCancer Science, 2009
- The expression and functional characterization of sigma (σ) 1 receptors in breast cancer cell linesCancer Letters, 2006
- In vitro characterization of radioiodinated (+)-2-[4-(4-iodophenyl) piperidino]cyclohexanol [(+)-pIV] as a sigma-1 receptor ligandBioorganic & Medicinal Chemistry, 2005
- SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivoBritish Journal of Cancer, 2003
- Characterization of radioiodinated (−)-ortho-iodovesamicol binding in rat brain preparationsLife Sciences, 2002
- Cloning and Functional Expression of the Human Type 1 Sigma Receptor (hSigmaR1)Biochemical and Biophysical Research Communications, 1996
- A proposal for the classification of sigma binding sitesTrends in Pharmacological Sciences, 1992